Latest Ratios: P/E Ratio -6.3x · EV/EBITDA N/A · ROE -24.5%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $396M | $131M | $2M | $4M | $69M | $12M | $940M | $1.1B | $7.7B | $34.0B | $2.7B |
| Enterprise Value | $263M | $-2489921 | $-7315600 | $-8027276 | $57M | $2M | $941M | $1.1B | $7.7B | $34.0B | $2.7B |
| P/E Ratio → | -6.30 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 16.14 | — | — | — | 68697.99 | 29612.99 | 130742.19 | 164354.03 |
| P/B Ratio | 0.81 | 1.01 | 0.31 | 0.36 | 5.50 | 1.65 | — | 206.31 | 1272.72 | 3992.07 | 235.65 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | -32.11 | — | — | — | 68384.47 | 29610.11 | 130716.51 | 163646.83 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | — | — | — | 100.0% | 480.8% | 100.0% | 100.0% |
| Operating Margin | — | — | — | -5228.0% | — | — | — | -56073.8% | -3176.5% | -5082.7% | -124135.2% |
| Net Profit Margin | — | — | — | -4920.0% | — | — | — | -54254.9% | -1894.2% | -6025.4% | -129724.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -24.5% | -24.5% | -153.6% | -103.4% | -143.7% | -20012.0% | — | -149.5% | -67.6% | -157.9% | -258.6% |
| ROA | -23.1% | -23.1% | -115.8% | -82.5% | -100.9% | -342.7% | -215.0% | -117.1% | -45.7% | -85.9% | -112.2% |
| ROIC | — | — | — | — | — | — | — | -231.2% | -173.5% | -1178.6% | -377.2% |
| ROCE | -26.3% | -26.3% | -155.5% | -107.9% | -138.1% | -1690.0% | -6279.0% | -144.0% | -86.9% | -95.6% | -169.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.02 | 0.03 | 0.03 | 0.03 | — | 0.06 | 0.83 | — | 0.33 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.03 | -1.29 | -1.07 | -0.96 | -1.40 | — | -0.94 | -0.12 | -0.78 | -1.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1677.10 | -1677.10 | -1202.17 | -819.00 | -1095.92 | -10.10 | -42.92 | -935.31 | -638.74 | -97.49 | -17.47 |
Net cash position: cash ($133M) exceeds total debt ($71000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 28.95 | 28.95 | 3.24 | 5.15 | 4.89 | 4.61 | 0.11 | 4.61 | 6.19 | 8.22 | 2.85 |
| Quick Ratio | 28.95 | 28.95 | 3.24 | 5.15 | 4.89 | 4.61 | 0.11 | 4.61 | 6.19 | 8.22 | 2.85 |
| Cash Ratio | 28.77 | 28.77 | 3.03 | 4.81 | 4.11 | 4.20 | 0.09 | 4.18 | 5.51 | 7.71 | 2.75 |
| Asset Turnover | — | — | — | 0.02 | — | — | — | 0.00 | 0.03 | 0.02 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 216.08 | — | — | — | 499.44 | 502.57 | 521.65 | 1428.28 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $56M | $1M | $456014 | $880305 | $12463 | $237390 | $237390 | $273240 | $219600 | $8345 |
Binary clinical trial failure
As reported in financial statements, the company's P/B ratio of 0.81 suggests that the market is currently pricing the equity below the value of its net assets, reflecting significant investor doubt regarding the future commercial viability of the lead clinical candidate.
The valuation discount relative to book value is a common phenomenon for pre-revenue biotech firms where the market assigns little to no terminal value to the pipeline. Investors should monitor whether this discount persists as clinical data readouts approach, as a failure to achieve primary endpoints would likely lead to further erosion of this valuation floor.
According to recent SEC filings, the company maintains a current ratio of 23.71, which provides an exceptionally high level of liquidity that significantly insulates the firm from short-term insolvency risks despite the absence of any recurring revenue streams to support ongoing operations.
This liquidity position is primarily a function of cash reserves rather than operational efficiency, as the company lacks the working capital cycle typical of commercial-stage entities. While this provides a comfortable runway, the lack of revenue means that liquidity will inevitably decline as clinical trial expenditures continue to accelerate.
Based on the provided financial data, metrics such as asset turnover and the cash conversion cycle are currently unavailable, which is consistent with the company's status as a pre-revenue entity focused entirely on clinical development rather than commercial sales or inventory management.
Analysts should avoid applying standard efficiency ratios to this business model, as the lack of revenue renders these metrics meaningless. The primary efficiency metric for this firm is the 'burn-to-milestone' ratio, which measures how effectively capital is deployed to reach critical regulatory data readouts.
As indicated by the company's negative net margins and lack of gross profit, traditional profitability ratios are frequently misapplied to this business model, obscuring the fact that the firm is currently in a capital-intensive investment phase rather than a mature operational phase.
Investors should focus on clinical milestone achievement and cash runway rather than net income or operating margins, which are structurally negative by design. Using P/E or EBITDA multiples to evaluate this company is fundamentally flawed, as these metrics fail to capture the binary nature of the underlying clinical assets.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PALI stock.
Palisade Bio, Inc.'s current P/E ratio is -6.3x. This places it at the 50th percentile of its historical range.
Palisade Bio, Inc.'s return on equity (ROE) is -24.5%. The historical average is -170.4%.
Based on historical data, Palisade Bio, Inc. is trading at a P/E of -6.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.